Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China

Xiaohua Hou, Shengliang Chen, Yali Zhang, Weihong Sha, Xiaofeng Yu, Hesham Elsawah, Afifi Fahmy Afifi, Hisham Raafat El-Khayat, Alaa Nouh, Mohamed Fathalla Hassan, Ayman Abdel Fatah, Isabel Rucker Joerg, Juan Manuel Sánchez Núñez, Rodolfo Osthoff Rueda, Grazyna Jurkowska, Michal Walczak, Ewa Malecka-Panas, Krzysztof Linke, Marek Hartleb, Gwendolyn Janssen-van Solingen, Xiaohua Hou, Shengliang Chen, Yali Zhang, Weihong Sha, Xiaofeng Yu, Hesham Elsawah, Afifi Fahmy Afifi, Hisham Raafat El-Khayat, Alaa Nouh, Mohamed Fathalla Hassan, Ayman Abdel Fatah, Isabel Rucker Joerg, Juan Manuel Sánchez Núñez, Rodolfo Osthoff Rueda, Grazyna Jurkowska, Michal Walczak, Ewa Malecka-Panas, Krzysztof Linke, Marek Hartleb, Gwendolyn Janssen-van Solingen

Abstract

Background and objective: Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS-Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide.

Methods: This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome III criteria in four countries (Poland, Egypt, Mexico and China).

Results: A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks 4 and 8 overall and in each country (overall: 11.8 at Week 4, 24.3 at Week 8; p < 0.001). Improvements were shown in all IBS-QOL subscales and scores. Symptoms and health economic outcomes were improved. Furthermore, the favourable safety profile of these treatments was confirmed in this study.

Conclusions: This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL.

Figures

Fig. 1
Fig. 1
Patient disposition (all patients)
Fig. 2
Fig. 2
Change from baseline, in Irritable Bowel Syndrome–Quality of Life (IBS-QOL) subscale scores at Weeks 4 and 8 in Poland (a), China (b), Egypt (c) and Mexico (d)
Fig. 2
Fig. 2
Change from baseline, in Irritable Bowel Syndrome–Quality of Life (IBS-QOL) subscale scores at Weeks 4 and 8 in Poland (a), China (b), Egypt (c) and Mexico (d)

References

    1. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease–specific, quality–of–life questionnaire. Am J Gastroenterol. 2000;95(4):999–1007. doi: 10.1111/j.1572-0241.2000.01941.x.
    1. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541–550. doi: 10.1097/MCG.0b013e318189a7f9.
    1. Kawanawa M, Drossman DA, Shonozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL–J) BioPsychoSoc Med. 2007;1:6. doi: 10.1186/1751-0759-1-6.
    1. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–660. doi: 10.1053/gast.2000.16484.
    1. Mönnikes H, Hecker H, Heymann–Mönnikes I. Predictive factors for therapeutic success in irritable bowel syndrome (IBS) in primary care (PrC) 2001. Z Gastroenterol. p. 39.
    1. Ji HZ, Wu XW, Xu XB, et al. Evaluating the clinical effect and quality of life in the elderly with functional bowel disorders after treatment with pinaverium bromide. J Clin Rehabil Tissue Eng Res. 2007;11(12):2275–2278.
    1. Patrick DL, Drossman DA, Ihunnaya OF, et al. Quality of life in persons with irritable bowel syndrome. Dig Dis Sci. 1998;43(2):400–411. doi: 10.1023/A:1018831127942.
    1. Winsemius A, Meuwsen IM, Boon C, et al. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002;56:659–662.
    1. MAPI Research Trust. .
    1. Drossman DA, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol. 2007;102:1442–1453. doi: 10.1111/j.1572-0241.2007.01283.x.
    1. Draft guidance for industry on irritable bowel syndrome—clinical evaluation of products for treatment: availability. Federal Register. 2010;75(55):13765–6.
    1. Bijkerk CJ, de Wit NJ, Muris JWM, et al. Outcome measures of irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol. 2003;98(1):122–127. doi: 10.1111/j.1572-0241.2003.07158.x.
    1. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28:10. doi: 10.1016/j.clinthera.2006.10.010.
    1. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005;17(3):332–340. doi: 10.1111/j.1365-2982.2005.00650.x.
    1. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538–1551. doi: 10.1053/j.gastro.2005.11.058.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe